Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.71 |
| ▸ | BID | P55957 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TACR3 | P29371 | 1/20 | 0.61 |
| ▸ | TACR1 | P25103 | 2/20 | 0.61 |
| ▸ | NMBR | P28336 | 4/20 | 0.60 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | BRS3 | P32247 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063740 | 0.89 | BCL2A1 (0.68) | BCL2A1BIDKMT2ATACR3TACR1 | |
| SCHEMBL6021350 | 0.86 | CTSL (0.66) | BCL2A1BIDKMT2ATACR3TACR1 | |
| SCHEMBL8999430 | 0.85 | MAPT (0.68) | BCL2A1BIDKMT2ATACR1MAPT | |
| SCHEMBL24719147 | 0.85 | BCL2A1 (0.64) | BCL2A1BIDKMT2ATACR3TACR1 | |
| SCHEMBL13827436 | 0.84 | MMP9 (0.69) | BCL2A1BIDTACR1MAPK1SMN1; SMN2 | |
| SCHEMBL30376874 | 0.84 | MMP9 (0.69) | BCL2A1BIDTACR1MAPK1SMN1; SMN2 | |
| SCHEMBL24814079 | 0.84 | MMP9 (0.69) | BCL2A1BIDTACR1MAPK1SMN1; SMN2 | |
| SCHEMBL6019857 | 0.84 | CTSL (0.80) | BCL2A1BIDKMT2ATACR3TACR1 | |
| SCHEMBL29540087 | 0.84 | BCL2A1 (0.80) | BCL2A1BIDKMT2ATACR3TACR1 | |
| SCHEMBL29539961 | 0.83 | ACE (0.72) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | BCL2A1 1740/4885BID 108/4885KMT2A 4608/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | BCL2A1 1740/4885BID 108/4885KMT2A 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.